Purgo Pipeline
Purgo Scientific is primarily dedicated to addressing unmet needs within orthopedic applications, serving both civilian and defense sectors. In addition, the Purgo team is actively exploring opportunities for the pouch in other areas, including pain management, oncology, and beyond.
Surgical Site Infection
By the Numbers in the U.S.
Surgical Site Infections Cost the U.S. Healthcare System
$10 BILLION ANNUALLY
And Impact Over 300,000 Patients a Year
#1
Cause of Healthcare Acquired Infections
9,000
Number of U.S. Patients that Die From SSI Annually
#1
Cause of Readmissions After Surgery
9.7
Average Number of Days in Hospital Due to SSI
Surgical Site Infection
By the Numbers in the U.S.
Surgical Site Infections Cost the U.S. Healthcare System
$10 BILLION ANNUALLY
And Impact Over 300,000 Patients a Year
#1
Cause of Healthcare Acquired Infections
9,000
Number of U.S. Patients that Die From SSI Annually
#1
Cause of Readmissions After Surgery
9.7
Average Number of Days in Hospital Due to SSI
What are Planktonic Bacteria?
- Individual bacteria.
- Float in a liquid medium like blood.
- Metabolically active.
- More susceptible to antibiotics.
- Readily controlled by host immune cells.
What are Bacterial Biofilms?
- Communities of bacteria.
- Primarily attach to solid surfaces.
- Metabolically inactive.
- Less susceptible to antibiotics.
- Can cause recurring infections.
What are Planktonic Bacteria?
- Individual bacteria.
- Float in a liquid medium like blood.
- Metabolically active.
- More susceptible to antibiotics.
- Readily controlled by host immune cells.
What are Bacterial Biofilms?
- Communities of bacteria.
- Primarily attach to solid surfaces.
- Metabolically inactive.
- Less susceptible to antibiotics.
- Can cause recurring infections.
The Solution
The Right Therapy
Purgo Pouch will deliver an effective tobramycin dose to kill biofilms.
The Right Place
Purgo Pouch targets infection by delivering tobramycin locally in the surgical wound site.
The Right Duration
Purgo Pouch sustains tobramycin delivery for up to 30 days, offering unparallelled versatility.
Purgo Pouch Is Superior To Current Clinical Approaches
SSI Treatment Options
Purgo Pouch Sustained Delivery Device*
Effective Planktonic Bacterial Control
Flexibility to Change Antibiotics
Continuous Daily Therapy
Effective Biofilm Eradication
Oral Antibiotic Administration
Effective Planktonic Bacteria Control
Flexibility to Change Antibiotics
Continuous Daily Therapy
Effective Biofilm Eradication
IV Antibiotic Administration
Effective Planktonic Bacteria Control
Flexibility to Change Antibiotics
Continuous Daily Therapy
Effective Biofilm Eradication
Antibiotic-Impregnated Beads
Effective Planktonic Bacteria Control
Flexibility to Change Antibiotics
Continuous Daily Therapy
Effective Biofilm Eradication
Local Antibiotic Powder or Lavage Application
Effective Planktonic Bacteria Control
Flexibility to Change Antibiotics
Continuous Daily Therapy
Effective Biofilm Eradication
*As shown in preclinical studies
Purgo Use Case Pathway
Product/Platform
Discovery
Pre-clinical
Phase 1
Orthopedic surgical site infection – treatment
Manage surgical site infections that affect bone such as in open fractures
Orthopedic surgical site infection – prophylaxis
Prevent surgical site infections from developing in, for example, open fractures
General surgical site infection – treatment
Manage infection present in soft tissue spaces
General surgical site infection – prophylaxis
Prevent infection from developing in soft tissue spaces
Pain management – post-operative
Provide post-surgical pain relief via sustained local anesthetic delivery
Oncology – solid tumors
Target tumors with local delivery of multimodal synergistic small molecule and/or antibody combinations (reduced systemic toxicity)
Bone growth and fracture healing – expedite
Locally deliver bone growth agents (bone morphogenetic protein) expediting fracture healing and bone growth in other applications
Purgo’s Pipeline
Orthopedic surgical site infection – treatment
Manage surgical site infections that affect bone such as in open fractures
Product/Platform
Discovery
Pre-clinical
Phase 1
Orthopedic surgical site infection – prophylaxis
Prevent surgical site infections from developing in, for example, open fractures
Product/Platform
Discovery
Pre-clinical
Phase 1
General surgical site infection – treatment
Manage infection present in soft tissue spaces
Product/Platform
Discovery
Pre-clinical
Phase 1
General surgical site infection – prophylaxis
Prevent infection from developing in soft tissue spaces
Product/Platform
Discovery
Pre-clinical
Phase 1
Pain management – post-operative
Provide post-surgical pain relief via sustained local anesthetic delivery
Product/Platform
Discovery
Pre-clinical
Phase 1
Oncology – solid tumors
Target tumors with local delivery of multimodal synergistic small molecule and/or antibody combinations (reduced systemic toxicity)
Product/Platform
Discovery
Pre-clinical
Phase 1
Bone growth and fracture healing – expedite
Locally deliver bone growth agents (bone morphogenetic protein) expediting fracture healing and bone growth in other applications
Product/Platform
Discovery
Pre-clinical
Phase 1